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Abstract
Introduction: Women with ductal hyperplasia including usual ductal hyperplasia (UDH) and atypical ductal
hyperplasia (ADH) have an increased risk of developing invasive ductal carcinoma (IDC) of breast. The importance
of several molecular markers in breast cancer has been of considerable interest during recent years such as p53
and estrogen receptor alpha (ERa). However, p53 nuclear accumulation and ERa expression have not been
assessed in ductal hyperplasia co-existing with ductal carcinoma in situ (DCIS) or IDC versus pure ductal hyperplasia
without DCIS or IDC.
Materials and methods: We investigated p53 nuclear accumulation and ERa expression in breast ductal
hyperplasia in a cohort of 215 Chinese women by immunohistochemistry (IHC), which included 129 cases of pure
ductal hyperplasia, 86 cases of ductal hyperplasia co-existing with DCIS (41 cases) or IDC (45 cases).
Results: Nuclear p53 accumulation was identified in 22.8% of ADH (31/136), 41.5% of DCIS (17/41) and 42.2% of
IDC (19/45), and no case of UDH (0/79). No difference in nuclear p53 accumulation was observed between pure
ADH and ADH co-existing with DCIS (ADH/DCIS) or IDC (ADH/IDC) (P > 0.05). The positive rate of ERa expression
was lower in ADH (118/136, 86.8%) than that in UDH (79/79, 100%) (P < 0.001), but higher than that in DCIS (28/
41, 68.3%) or IDC (26/45, 57.8%) respectively (P < 0.001). The frequency of ERa expression was lower in ADH/DCIS
(23/29, 79.31%) and ADH/IDC (23/30, 76.67%) than that in pure ADH (72/77, 93.51%) respectively (P < 0.05). There
was a negative weak correlation between p53 nuclear accumulation and ERa expression as for ADH (coefficient
correlation -0.51; P < 0.001).
Conclusions: Different pathological types of ductal hyperplasia of breast are accompanied by diversity in patterns
of nuclear p53 accumulation and ERa expression. At least some pure ADH is molecularly distinct from ADH/CIS or
ADH/IDC which indicated the two types of ADH are molecularly distinct entities although they have the same
morphological appearance.
Introduction
Worldwide, breast cancer comprises 10.4% of cancer
incidence among women, making it the second most
common type of non-skin cancer (after lung cancer)
and the fifth most common cause of cancer death [1].
In the last two decades, the incidence and mortality of
breast cancer have climbed sharply in China, thus
attracting increased attention of researchers [2].
Historically, beast cancer emerges by a multistep process
which can be broadly equated to transformation of nor-
mal cells via the steps of hyperplasia, premalignant
lesions and in situ carcinoma, invasive carcinoma which
supported by evidences from clinical, pathological, and
genetic studies [3-5]. It is a heterogeneous disease that
encompasses a wide range of pathological entities and
clinical behaviors, thus posing great challenges in under-
standing the precise molecular mechanisms of breast
carcinogenesis [3]. Recent studies show that about 8% to
9% of women with benign lesions will be subsequently
developed into invasive breast cancer [6,7]. It is quite
unclear how invasive breast cancer develops through
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hyperplasia (UDH) and atypical ductal hyperplasia
(ADH) [8].
The importance of some molecular markers in breast
cancer has been of considerable interest during recent
years, not only as prognostic markers, but also as predic-
tors of response to therapy. p53 is the primary arbiter of
the mammalian cells’ response to stress. In its normal
form, p53 can be involved in the induction of apoptosis
and thus has a regulatory function over the cell cycle. In
its mutant form, p53 inhibits apoptosis, loses control on
cell cycle progression and thus helps tumor formation
[9]. Nuclear p53 accumulation which associates with p53
mutation is one of the most common events during
breast carcinogenesis [10-12]. Epidemiological and
experimental evidences implicated oestrogens in the
aetiology of breast cancer [13-17]. The biological actions
of estrogens are mediated by binding to one of two speci-
fic estrogen receptors (ERs), ERa or ERb,w h i c hb e l o n g
to a family of ligand-regulated transcription factors [18].
ERa has been widely accepted as a prognostic marker
and a predictor for endocrine therapy response of breast
cancer [19,20]. In general, ERa-negative breast cancers
are more aggressive and unresponsive to antiestrogens
[21]. However, p53 nuclear accumulation and ERa
expression have not been assessed in ductal hyperplasia
co-existing with ductal carcinoma in situ (DCIS) or inva-
sive ductal carcinoma (IDC) versus pure ductal hyperpla-
sia without DCIS or IDC. The aims of this study were: (a)
to assess p53 nuclear accumulation and ERa expression
in pure ductal hyperplasia and ductal hyperplasia co-
existing with DCIS or IDC; (b) to explore if there is a dif-
ferential expression pattern of ERa and p53 nuclear
accumulation between pure ductal hyperplasia and ductal
hyperplasia co-existing with DCIS or IDC.
Materials and methods
Patients and tissues: 129 cases of pure ductal hyperpla-
sia of breast, 86 cases of ductal hyperplasia co-existing
with DCIS (41 cases) and IDC (45 cases) were collected
from surgical samples of wom e na tt h eF i r s tA f f i l i a t e d
Hospital of China Medical University between 2005 and
2010. None of patients undergo chemotherapy, radio-
therapy or adjuvant treatment before operation. Patients’
ages ranged from 21 to 82, with an average age of 43.8
years old. Each case was reviewed independently by 2
pathologists (Chui-feng Fan and Min Song) with a sub-
specialty focus in breast pathology, and only those cases
that both pathologists finally reached the unanimous
diagnosis were used. In case of insufficient or unattain-
able material, original tissue blocks were reprocessed
and new slides were created. The pathological types of
breast ductal hyperplasia lesions have been classified
according to WHO’s criteria which published by
Tavassoli FA et al [22]. All sections were reviewed for a
comprehensive list of pathologic features, including mar-
gins (close margins were defined as tissue-free margins
< 1 mm), the presence of concomitant UDH, ADH,
DCIS and IDC. The pathological types of breast ductal
hyperplasia lesions were summarized in Table 1. The
cases of breast ductal hyperplasia lesions include 79
cases of UDH and 136 cases of ADH (16 cases of ductal
intraepithelial neoplasia 1A (DIN 1A) and 120 cases of
ductal intraepithelial neoplasia 1B (DIN 1B)). The study
was approved by the regional ethics committee at China
Medical University.
Immunohistochemistry: Formalin-fixed and paraffin-
embedded specimens were cut into 4 μm-thick sections,
which were subsequently de-waxed and hydrated.
Immunohistochemical staining for ERa (sc-542, Santa
Cruz, 1:200) and p53 (sc-47698, Santa Cruz, 1:100) were
performed using UltraSensitive™ S-P kits (Maixin-Bio;
P.R. China) according to the manufacturer’s instructions
and using the reagent supplied within the kit. For the
negative control, phosphate-buffered saline (PBS) was
used in place of the primary antibodies. We also
adopted the German semi-quantitative scoring system in
considering the staining intensity and area extent, which
has been widely accepted and used in previous studies
[23-25]. Every lesions was given a score according to the
intensity of the nucleic staining (no staining = 0, weak
staining = 1, moderate staining = 2, strong staining = 3)
and the extent of stained cells (0% = 0, 1-10% = 1,
11-50% = 2, 51-80% = 3, 81-100% = 4; negative means
0% area staining, focally positive means 1-80% area
staining, diffusely positive means 81-100% area staining).
The final immunoreactive score was determined by mul-
tiplying the intensity scores with the extent of positivity
scores of stained cells, with the minimum score of 0 and
am a x i m u ms c o r eo f1 2[ 2 4 - 2 6 ] .S l i d e sw e r ei n d e p e n -
dently examined by 2 pathologists (Chui-feng Fan and
Min Song) as previously mentioned; however, if there
was a discrepancy in individual scores both pathologists
reevaluated together by reaching a consensus agreement
before combining the individual scores. To obtained sta-
tistical results, a final score equal to or less than 1 was
considered as negative, while scores of 2 or more were
considered as positive.
Table 1 Breast ductal hyperplasia lesions of the different
pathological types
Pure type With DCIS With IDC Total
UDH 52 12 15 79
ADH 77 29 30 136
DIN 1A 1 9 6 16
DIN 1B 76 20 24 120
Total 129 41 45 215
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the c2 test. The correlation between p53 nuclear accu-
mulation and ERa expression was tested by using the
Pearson chi-square test. All statistical analyses were per-
formed using SPSS 13.0 for Windows (SPSS Inc., Chi-
cago, IL, USA). Statistical significance in this study was
set at P < 0.05. All reported P values are two-sided.
Results
p53 nuclear accumulation in ductal hyperplasia of breast
T h ep h e n o t y p i ce x p r e s s i o n patterns of p53 in breast
ductal hyperplasia were shown in Figure 1. Table 2
showed p53 nuclear accumulation in ductal hyperplasia
of breast. No p53 nuclear accumulation was found in
UDH (0/79) regardless of co-existing DCIS or IDC.
p53 nuclear accumulation was detectable in 22.8% of
ADH (31/136), higher than that in UDH (P < 0.001),
lower than that in DCIS (41.5%, 17/41) or in IDC
(42.2%, 19/45) respectively (P < 0.01). No difference in
nuclear p53 accumulation were observed between pure
ADH (14/77) and ADH/DCIS (9/29) (18.2% vs. 31.0%,
P > 0.05) or ADH/IDC (8/30) (18.2% vs. 26.7%,
P > 0.05).
ERa expression in ductal hyperplasia of breast
The phenotypic expression patterns of ERa protein in
breast ductal hyperplasia were shown in Figure 2. The
positive rate of ERa expression in breast ductal hyper-
plasia was summarized in Table 2.The positive rate of
ERa expression was lower in ADH (118/136, 86.8%)
than that in UDH (79/79, 100%) (P <0 . 0 0 1 ) ,b u th i g h e r
than that in DCIS (28/41, 68.3%) or IDC (26/45, 57.8%)
respectively (P < 0.001). The frequency of ERa expres-
sion was lower in ADH/DCIS (23/29, 79.31%) and
ADH/IDC (23/30, 76.67%) than that in pure ADH (72/
77, 93.51%) respectively (P < 0.05).
Correlation between p53 nuclear accumulation and ERa
expression
There was no correlation between p53 nuclear accumu-
lation and ERa expression in any type of ductal hyper-
plasia of breast (P > 0.05). But as shown in Figure 3.
p53 nuclear accumulation and ERa expression had
inverse patterns of alterations in ADH of breast. As for
ADH, which shown in Table 3 the correlation coeffi-
cient was -0.512 between p53 nuclear accumulation and
ERa expression (P < 0.001).
Figure 1 Immunohistochemical staining of noninvasive breast lesions with antibody against p53. p53 nuclear accumulation was not
found in epithelial cells of normal ducts (a) and usual ductal hyperplasia (b) of breast. p53 positive staining in atypical ductal hyperplasia (c): the
bigger arrow shows a breast duct filled with cells with atypical hyperplasia. The cells are quite identical in size and shape. Staining of p53 is seen
in some nuclears (> 10%). The little arrow shows a normal duct without p53 nuclear accumulation. p53 positive staining in ductal carcinoma in
situ (d): the bigger arrow shows a ductal carcinoma in situ with positive staining of p53 in nuclears (> 10%). The little arrow shows necrosis in
the ductal carcinoma in situ. (× 40)
Mao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:112
http://www.jeccr.com/content/29/1/112
Page 3 of 7Discussion
p53 is located on human chromosome 17p and its
encoding protein mediates its tumor suppressor function
via the transcriptional regulation or repression of var-
ious genes [26-29]. p53 had been suggested to be pre-
dictive of risk for subsequent breast carcinogenesis, p53
nuclear accumulation has been identified as a poor
prognostic marker in breast cancer [30]. The immuno-
histochemical detection of nuclear p53 protein accumu-
lation is highly associated with p53 gene mutations in
breast cancer tissues [31], in benign breast lesions it has
been associated with elevated risk of progression to
Table 2 p53 nuclear accumulation and ERa expression in ductal hyperplasia of breast
Total no. p53 nuclear accumulation P-value ERa expression P-value
+- + -
UDH
Pure type 52 0 52 > 0.05 52 0 > 0.05
With DCIS 12 0 12 12 0
With IDC 15 0 15 15 0
ADH
Pure type 77 14 63 > 0.05 72 5 <0.05
With DCIS 29 9 20 c2 = 2.31 23 6 c2 = 7.12
With IDC 30 8 22 23 7
DCIS
With UDH 12 5 7 > 0.05 84 > 0.05
With ADH 29 12 17 c2 = 0.00 20 9 c2 = 0.00
IDC
With UDH 15 7 8 > 0.05 11 4 > 0.05
With ADH 30 12 18 c2 = 0.18 15 15 c2 = 1.38
Figure 2 ERa expression in noninvasive breast lesions.a :E R a staining in epithelial cells of normal ducts (smaller arrow) and usual ductal
hyperplasia (bigger arrow) of breast was located in nuclear. b: ERa staining was seen in all epithelial cells of a normal duct (smaller arrow) but
was reduced in cells in a co-existing duct with atypical ductal hyperplasia (bigger arrow). c: The arrow shows a breast duct with atypical ductal
hyperplasia with positive staining of ERa (> 10%) which was absent in some cells. d: ERa staining in a ductal carcinoma in situ was negative
(< 10%). The arrow shows the necrosis. (× 40)
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accumulation occurred in ADH but not in UDH regard-
less of co-existing DCIS or IDC. Nuclear p53 accumula-
tion was not significantly different between pure ADH
and ADH co-existing DCIS or IDC. It was in accordance
with previous studies that UDH was considered to
represent a benign proliferation of ductal epithelial cells,
whereas ADH represents the first clonal neoplastic
expansion of these cells [33]. It is clear that not all
ADH will progress into DCIS or IDC during the
patient’s lifetime. However, we found no differences in
p53 expression between pure ADH and ADH co-exist-
ing with DCIS or IDC. Maybe there are more molecular
alteration counteracts with p53 or p53 itself is an initia-
tive factor in breast carcinogenesis.
Epidemiological and experimental evidences impli-
cated estrogens in the aetiology of breast cancer which
play a central role in the growth and differentiation of
normal breast epithelium [13-17]. ERa status has also
been shown to have prognostic value in breast cancer,
although the importance of hormone-receptor status lies
rather as a predictor of response to endocrine therapy.
A potential mechanism of hormone resistance is the
acquired loss of ERa gene expression at the transcrip-
tional level during breast carcinogenesis [34-37]. Here,
we found ERa expression in all UDH regardless of co-
existing DCIS or IDC though there were occasionally
sporadic staining patterns, and there was significant loss
of ERa expression in ADH and breast carcinoma, ERa
was decreasingly expressed from UDH to ADH, DCIS
or IDC. Our findings support that UDH and ADH are
different ductal hyperplasia lesions of breast, they have
pathological types which accompanied by diversity in
pattern of genetic expression.
In our study, a significant difference in ERa expres-
sion was found between pure type ADH and ADH/
DCIS or ADH/IDC, suggested that the subsets of ADH/
CIS or ADH/IDC may have different molecular genetics
in comparison with the pure ADH without DCIS or
IDC. ADH and ADH/DCIS or ADH/IDC have similar
morphology, but have different ERa expression. Further-
more, we found a negative weak correlation between
p53 nuclear accumulation and ERa expression as for
ADH (coefficient correlation -0.512; P < 0.001). Experi-
ments in vitro suggested that ERa opposes p53-
mediated apoptosis in breast cancer cells by Sayeed A
[38]. Shirley SH performed animal experiments to show
that p53 genotype was correlated with ER expression
and response to tamoxifen in mammary tumors arising
in mouse mammary tumor virus-Wnt-1 transgenic
mice. They changed the p53 expression of MCF-7 cells
with doxorubicin or ionizing radiation, ER expression
was also changed. In MCF-7 transfected with WT p53,
transcription from the ER promoter was increased
8-fold, they concluded that p53 may regulate ER expres-
sion [39]. Based on our study, further investigation
about the relation between p53 and ER appear to be
warranted in breast carcinogenesis.
ERa loss in breast carcinoma is considered an unfa-
vorable factor for patients partly due to the accordingly
reduced sensitivity of cancer cells to endocrine therapy.
There are patients with ERa (-) breast carcinomas but
has ERa ( + ) surrounding breast tissues including those
have atypical hyperplasia. These patients are often not
supposed to be given the endocrine therapy. But what
the ERa ( + ) surrounding breast tissues means to the
endocrine therapy protocol is still mysterious and intri-
guing. Based on our study, ERa l o s sm a yb ep a r t l yd u e
Figure 3 A case of ADH of breast with concurrent increased p53 nuclear accumulation (a) and reduced ERa expression. There were
some cells (> 10%) with weak p53 staining in a. While some cells (> 10%) were absent of ERa staining in b.
Table 3 Correlation of p53 nuclear accumulation with ER?
expression in ADH
p53 unclear accumulation
+-
ERa expression + 17 101 r = -0.512
ERa expression - 14 4 P < 0.001
Correlation between p53 nuclear accumulation and ERa expression; r =
correlation coefficient (n =1 3 6 ) .
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carcinoma. On the other hand there also may be some
other unknown molecules involved in the interplays
with ERa loss instead of p53 nuclear accumulation. To
restore the ERa ( + ) phenotype of breast carcinogenesis
for better outcome of endocrine therapy, further investi-
gation of molecules involved is necessary.
In summary, we found the diversity of the pathological
type is accompanied by diversity in pattern of genetic
expression. And at least some pure ADH is molecularly
distinct from ADH/CIS or ADH/IDC which indicated
the two types of ADH are molecularly distinct entities
although they have the same morphological appearance.
Molecular differences between pure and synchronous
lesions support re-evaluation of current models of breast
cancer initiation, progression, and risk.
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